Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00504205 · ClinicalTrials.gov registry record · NA
MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma
A NA study, sponsored by Astex Pharmaceuticals.
- Terminated
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT00504205 is a NA study that was terminated before completion, run by Astex Pharmaceuticals. The registered enrollment target is 30 participants.
The verdict
NCT00504205, a NA study, was terminated before completion, sponsored by Astex Pharmaceuticals.
- TERMINATED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: MP470 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial is studying the side effects and best dose of MP470 in treating patients with unresectable or metastatic refractory solid tumor, Hodgkin's lymphoma, or non-Hodgkin's lymphoma.
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- PROCEDURE positron emission tomography
- DRUG multitargeted receptor tyrosine kinase inhibitor MP470
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2007-05 |
| Est. Completion | 2010-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00504205
The ClinicalTrials.gov registry entry for NCT00504205 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astex Pharmaceuticals, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00504205 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00504205 about?
NCT00504205 is a clinical study titled "MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma". RATIONALE: MP470 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial is studying the side effects and best dose of MP470 in treating patients with unresectable or metastatic refractory solid tumor, Hodgkin's lymphoma, or non-Hodgk...
What is the current status of trial NCT00504205?
This trial is currently terminated. It is a NA study. The enrollment target is 30 participants. The study started on 2007-05. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00504205?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), positron emission tomography (PROCEDURE), multitargeted receptor tyrosine kinase inhibitor MP470 (DRUG).
Who is sponsoring clinical trial NCT00504205?
This trial is sponsored by Astex Pharmaceuticals, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.